Nyxoah Q3 Revenue €9.2M; New Risk Factor Flags Nasdaq $1.00 Bid-Price Delisting Threat
NYXH is trading near its 52-week low of $0.8 (1.4% above the low).
Summary
Nyxoah reported Q3 2026 global net revenue of €9.2 million (up 19% sequentially, U.S. up 29%) and, in new supplemental risk factors, warned its shares could fall below Nasdaq's $1.00 minimum bid price and face delisting.
Key Events · Earnings and Guidance · NYXH
-
Nasdaq Bid-Price Delisting Risk Disclosed
New supplemental risk factors state the shares must not close below $1.00 for 30 consecutive trading days; a deficiency letter could follow, with a possible 180-calendar day grace period and delisting absent a reverse share split, which would require shareholder approval. The stock trades at $0.811.
-
Q3 Revenue €9.2M, U.S. Up 29%
Global net revenue was €9.2 million, 19% sequential growth, with U.S. net revenue of €6.7 million up 29% sequentially; gross margin was 63.1%.
-
Cash Falls to €77.1M
Cash, cash equivalents and financial assets totaled €77.1 million at September 30, 2026, down from €97.8 million at June 30, 2026, against a Q3 operating loss of €21.9 million.
-
PMA Supplement Filed for CCC
Nyxoah submitted a PMA supplement to the FDA to expand Genio's U.S. indication to Complete Concentric Collapse patients, supported by a 77.2% 12-month AHI responder rate in the ACCCESS study.
Analysis · NYXH · Industrial Applications And Services
Commercial traction is real: global net revenue of €9.2 million rose 19% sequentially, and U.S. revenue of €6.7 million climbed 29%. The more consequential item, however, sits in the supplemental risk factors. With the stock at $0.811, Nyxoah now explicitly warns that it can fall below Nasdaq's $1.00 minimum bid price; after 30 consecutive trading days that triggers a deficiency letter, a possible 180-day grace period, and delisting if a reverse split (requiring shareholder approval) is not implemented. A previously implicit listing worry has become a disclosed, dated risk. Cash of €77.1 million at September 30 is down from €97.8 million at June 30, so the runway is finite while the operating loss was still €21.9 million in the quarter. Offsets that could broaden the addressable U.S. market: the PMA supplement for Complete Concentric Collapse patients and the 11-13% CMS 2027 reimbursement increases.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NYXH was trading at $0.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $82.6M. The 52-week trading range was $0.80 to $5.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.